Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 3Phase 2 3Phase 1/2 2Phase 1 2Phase 4 1Phase 2/3 1

Status

Suspended 1Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

CNS 1

Conditions

Neoplasms 1Glioblastoma 1Depression 1Anxiety Disorders 1

Interventions

pembrolizumab 410Cyclophosphamide 394Carboplatin 306Gemcitabine 286Nivolumab 276Paclitaxel 274Cisplatin 252Radiotherapy 225Dexamethasone 210Bevacizumab 209fludarabine 192Docetaxel 187Rituximab 183Capecitabine 171Oxaliplatin 158Lenalidomide 157Fluorouracil 152Temozolomide 138Cytarabine 135Etoposide 128Irinotecan 124Cetuximab 123fludarabine phosphate 120Injections 118venetoclax 116Ipilimumab 115Doxorubicin 114Azacitidine 108130-nm albumin-bound paclitaxel 108Pemetrexed 107

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1/2 × Interventional × Niacin × Clear all
NCT04677049 2026-01-02

Study of Niacin in Glioblastoma

AHS Cancer Control Alberta

Phase 1/2 Suspended
59 enrolled
CNS

Glioblastoma

NCT00302744 2025-03-13

Effects of Psilocybin in Advanced-Stage Cancer Patients With Anxiety

Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center

Phase 1/2 Completed
12 enrolled

Anxiety Disorders, Depression, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡